Managing cardiovascular risk in type 2 diabetes: evidence into primary care practice (Promotional content from AstraZeneca) | GPnotebook TV

This site is intended for UK healthcare professionals

This video presentation has been organised and funded by AstraZeneca

Managing cardiovascular risk in type 2 diabetes: evidence into primary care practice (Promotional content from AstraZeneca)

17 September 2020

Sponsored

Click here to access the Forxiga (dapagliflozin) prescribing information

Please note: Forxiga (dapagliflozin) is indicated for use in glycaemic control and is not indicated for reduction in cardiovascular events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033

GB-23660 September 2020

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

This website is for UK healthcare professionals

To continue, please confirm that you are a UK healthcare professional.

We use anonymous cookies to generate usage statistics. Please click here to find out more.